BRCA1 and breast carcinoma: Several professional guidelines including those from the American Society of Breast Surgeons (ASBrS), the American Society of Clinical Oncology (ASCO) [3], and the National Comprehensive Cancer Network (NCCN) support consideration of CPM among BRCA1/2 positive women due to its demonstrated effectiveness in managing secondary breast cancer risk in terms of life years and quality-adjusted life years gained and cost saving when compared with breast cancer screening.